Artemis Therapeutics (OTC: ATMS) is a clinical-stage biopharmaceutical company focused on the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. The company’s lead product candidate, artemisone, is a synthetic artemisinin derivative with anti-viral and anti-parasitic properties. The company is currently evaluating artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (HCMV) infection, Artemis is also developing artemisone for the treatment of other virus and parasitic-related clinical indications. For more information, visit the company’s website at www.artemis-therapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
